BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS)

$0.179 0.009 (5.2941%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 61

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) News Sources

BioVaxys Technology Announces Conversion of Debentures

22-10-2025

yahoo.com

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES

28-10-2025

yahoo.com

BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

30-10-2025

yahoo.com

BioVaxys Announces Extension of Life Offering Closing Date

11-11-2025

yahoo.com

BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

19-11-2025

yahoo.com

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

17-12-2025

yahoo.com

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

08-01-2026

yahoo.com

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

20-01-2026

yahoo.com

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

29-01-2026

yahoo.com

BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

10-03-2026

yahoo.com

BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) Sentiment Trend

0 25 50 75 100 57 39 64 55 49 74 81 63 61 71 22-10-2025 28-10-2025 30-10-2025 11-11-2025 19-11-2025 17-12-2025 08-01-2026 20-01-2026 29-01-2026 10-03-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) FAQs

toggle

What is the current price of BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS)?

The current price of BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) is $0.179.


toggle

BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) absolute price change since previous trading day?

The absolute price change of BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) since the previous trading day is $0.009.


toggle

BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) percentage price change since previous trading day?

The percentage price change of BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) since the previous trading day is 5.2941%.


toggle

What is the most recent average sentiment score for BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS)?

The most recent average sentiment score for BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) is 61 out of 100.


toggle

What is the most recent average sentiment for BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS)?

The most recent sentiment for BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS) is .


SEC-8K** Filing Available For BIOVAXYS TECHNOLOGY CORP (BVAXF:OTCMKTS)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.